scholarly journals Characterization of HIV-1 from patients with virological failure to a boosted protease inhibitor regimen

2011 ◽  
Vol 83 (3) ◽  
pp. 377-383 ◽  
Author(s):  
Marie Rathcke Lillemark ◽  
Jan Gerstoft ◽  
Niels Obel ◽  
Gitte Kronborg ◽  
Court Pedersen ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Virological Failure ◽  
Protease Inhibitor Regimen ◽  
Inhibitor Regimen ◽  
Hiv 1

Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults

2008 ◽  
Vol 62 (4) ◽  
pp. 852-852
Author(s):  
J. van der Lugt ◽  
R. S. Autar ◽  
S. Ubolyam ◽  
E. F. Garcia ◽  
J. Sankote ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Short Term ◽  
Protease Inhibitor Regimen ◽  
Term Efficacy ◽  
Treatment Naïve ◽  
Inhibitor Regimen ◽  
Hiv 1

Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen

AIDS ◽  
2011 ◽  
Vol 25 (17) ◽  
pp. 2143-2148 ◽  
Author(s):  
Lucile Larrouy ◽  
Charlotte Charpentier ◽  
Roland Landman ◽  
Catherine Capitant ◽  
Corine Chazallon ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Protease Inhibitor Regimen ◽  
Inhibitor Regimen ◽  
Hiv 1

scholarly journals Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults

2008 ◽  
Vol 61 (5) ◽  
pp. 1145-1153 ◽  
Author(s):  
J. van der Lugt ◽  
R. S. Autar ◽  
S. Ubolyam ◽  
E. F. Garcia ◽  
J. Sankote ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Short Term ◽  
Protease Inhibitor Regimen ◽  
Term Efficacy ◽  
Treatment Naïve ◽  
Inhibitor Regimen ◽  
Hiv 1

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir

2005 ◽  
Vol 68 (1) ◽  
pp. 27-35 ◽  
Author(s):  
Louise Doyon ◽  
Sonia Tremblay ◽  
Lise Bourgon ◽  
Elizabeth Wardrop ◽  
Michael G. Cordingley
Keyword(s):  
Protease Inhibitor ◽  
Hiv 1

scholarly journals Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

2009 ◽  
Vol 53 (7) ◽  
pp. 2934-2939 ◽  
Author(s):  
Constance Delaugerre ◽  
Philippe Flandre ◽  
Marie Laure Chaix ◽  
Jade Ghosn ◽  
François Raffi ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Triple Therapy ◽  
Virological Failure ◽  
Therapy Group ◽  
Resistance Mutation ◽  
Resistance Testing ◽  
Initial Screening ◽  
Resistance Mutations ◽  
Cd4 Cell Count ◽  
Hiv 1

ABSTRACT The MONARK study was a pilot randomized trial comparing the safety and efficacy of lopinavir-ritonavir (LPV/r) monotherapy to those of LPV/r-zidovudine-lamivudine triple therapy for antiretroviral-naïve human immunodeficiency virus type 1 (HIV-1)-infected patients. Resistance testing was performed at the time of initial screening and at the time of virological failure (defined to include low-level viremia with >50 and <400 HIV-1 virus RNA copies/ml of plasma). Changes from the baseline sequences, including mutations noted on the 2008 International AIDS Society—USA list of resistance-associated protease mutations, were considered. Drug resistance testing was performed for 38 patients (5 of 53 on triple therapy and 33 of 83 on monotherapy). By week 96 (W96), virus samples from 18 of 33 patients in the monotherapy arm showed changes from baseline sequences, and 5 of these patients had viruses with major protease inhibitor (PI) resistance-associated mutations (M46I at W40, L76V at W48, M46I and L76V at W48, L10F and V82A at W72, and L76V at W84). Data on virus phenotypes detected at the time of initial screening and the time of virological failure were available for four patients in whom major PI resistance mutations developed, and these data revealed a mean increase of 2.2-fold (range, 0.75- to 4.6-fold) in the LPV 50% inhibitory concentration. All three patients in whom the L76V PI resistance mutation developed were infected with HIV-1 subtype CRF02_AG. In the triple-therapy group, no major PI resistance mutation was selected among the three patients with protease changes by W48. No association between the baseline CD4 cell count and the viral load, the W4 and final viral loads, or the final LPV trough concentration and the emergence of a major PI resistance mutation was found. Major PI resistance-associated mutations were detected in 5 (6%) of 83 patients treated with LPV/r monotherapy, suggesting that LPV/r monotherapy is an inappropriate first option. The mutation L76V may be considered in further studies of lopinavir resistance.

Limitations of a Simplification Antiretroviral Strategy for HIV-Infected Patients with Decreasing Adherence to a Protease Inhibitor Regimen

2006 ◽  
Vol 7 (4) ◽  
pp. 210-214 ◽  
Author(s):  
J. Moya ◽  
J.L. Casado ◽  
L. Aranzabal ◽  
A Moreno ◽  
A. Antela ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Protease Inhibitor Regimen ◽  
Inhibitor Regimen

Open-Label Study of a Twice-Daily Indinavir 800-mg/Ritonavir 200-mg Regimen in HIV-Infected Adults Failing a Protease Inhibitor Regimen

2002 ◽  
Vol 31 (5) ◽  
pp. 483-487 ◽  
Author(s):  
Harold P. Katner ◽  
David P. Paar ◽  
Jeffrey P. Nadler ◽  
Erin H. Jensen ◽  
Helene M. Wilson ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Protease Inhibitor Regimen ◽  
Inhibitor Regimen
Sign in / Sign up

Export Citation Format

Share Document